Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors
- PMID: 16625865
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors
Abstract
Peptide receptor radionuclide therapy (PRRT) holds great promise for the future regarding the treatment of various cancers. With the use of radiolabelled peptides, which bind with high affinity to their receptors on cancer cells, it is possible to target the cancer efficiently. In gastroenteropancreatic tumors, radiolabelled somatostatin analog therapy has proven to be effective. Dose-limiting organs are the bone marrow and the kidneys. With the currently used dose schemes and kidney protection, PRRT is relatively safe and serious side-effecs are rare. Which radiolabelled somatostatin analog can be regarded as the most effective therapy cannot be concluded from the available literature. Also, the development of therapy strategies with combinations of different radionuclides and or peptides is of interest as these strategies may provide an increase in therapeutic efficacy in the future.
Similar articles
-
[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].Orv Hetil. 2011 Mar 6;152(10):392-7. doi: 10.1556/OH.2011.29057. Orv Hetil. 2011. PMID: 21354955 Hungarian.
-
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):347-51. Eur Rev Med Pharmacol Sci. 2010. PMID: 20496546 Review.
-
Beta-emitting radionuclides for peptide receptor radionuclide therapy.Curr Top Med Chem. 2012;12(23):2686-93. doi: 10.2174/1568026611212230006. Curr Top Med Chem. 2012. PMID: 23339764 Review.
-
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.Neuroendocrinology. 2009;90(2):220-6. doi: 10.1159/000225951. Epub 2009 Aug 28. Neuroendocrinology. 2009. PMID: 19713714
-
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.Eur J Nucl Med. 2001 Sep;28(9):1421-9. doi: 10.1007/s002590100502. Eur J Nucl Med. 2001. PMID: 11585303 Review.
Cited by
-
Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.Semin Intervent Radiol. 2013 Mar;30(1):28-38. doi: 10.1055/s-0033-1333651. Semin Intervent Radiol. 2013. PMID: 24436515 Free PMC article. Review.
-
Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?Cancer Biother Radiopharm. 2008 Aug;23(4):383-97. doi: 10.1089/cbr.2007.0523-U. Cancer Biother Radiopharm. 2008. PMID: 18771343 Free PMC article.
-
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1386-96. doi: 10.1007/s00259-010-1388-2. Epub 2010 Feb 25. Eur J Nucl Med Mol Imaging. 2010. PMID: 20182713 Free PMC article.
-
Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1968-76. doi: 10.1007/s00259-009-1196-8. Eur J Nucl Med Mol Imaging. 2009. PMID: 19585115 Free PMC article.
-
[111In]In/[177Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results.Pharmaceutics. 2023 Feb 26;15(3):776. doi: 10.3390/pharmaceutics15030776. Pharmaceutics. 2023. PMID: 36986637 Free PMC article.